IVERIC bio, Inc. reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.
The inducement grants consisted of 15,745 restricted stock units for shares of the Company’s common stock. The restricted stock units vest with respect to 25% of the shares underlying the units on June 1, 2024 and 6.25% of the shares underlying the units on the first day of each of the subsequent 12 calendar quarters (July 1, 2024, October 1, 2024, January 2, 2025, April 1, 2025, July 1, 2025, October 1, 2025, January 2, 2026, April 1, 2026, July 1, 2026, October 1, 2026, January 2, 2027, and April 1, 2027). The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.
Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.
ISEE-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005377/en/
Investor / Media Contact:
Iveric Bio
Kathy Galante
Senior Vice President, Investor Relations
kathy.galante@ivericbio.com
Media Contact:
Jeannie Neufeld
Senior Director, Public Relations and Communications
Jeannie.neufeld@ivericbio.com
Source: IVERIC bio, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20230602005377/en
